Kirk Trisler

Kirk is a scientist and executive with more than 15 years of biotechnology experience focused on process development and cGMP manufacturing in the radioimmunotherapy, cell therapy, and gene therapy spaces. Following completion of his post-doctoral studies in radioimmunotherapy at Stanford University School of Medicine, he was instrumental in the development and approval of Bexxar (Iodine 131 Tositumomab) at Coulter Pharma (acquired by Corixa). He subsequently held CMC leadership roles at Genitope, Geron, and Gritstone Oncology where he was the Senior VP of Manufacturing and Product Development. Kirk earned his doctorate in immunology from the University of South Florida College of Medicine.